196 citations,
September 2016 in “JCI insight” Ruxolitinib effectively regrows hair in most patients with severe hair loss.
119 citations,
October 2011 in “Journal of Veterinary Internal Medicine” Rhodococcus equi causes severe pneumonia in young foals, and effective vaccines are needed due to foals' weak immune responses.
60 citations,
July 2020 in “ACS Nano” Using CRISPR for gene editing in the body is promising but needs better delivery methods to be more efficient and specific.
50 citations,
December 1999 in “British Journal of Dermatology” Finasteride improves hidradenitis suppurativa but not for child-bearing women.
49 citations,
August 2018 in “International Journal of Dermatology” Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
35 citations,
May 2008 in “Journal of Clinical Oncology” A cancer patient died from a severe skin reaction after taking the drug cetuximab.
29 citations,
February 2016 in “International Journal of Dermatology” People with lichen planus are more likely to have dyslipidemia, especially higher triglyceride levels.
24 citations,
June 2018 in “Reviews in endocrine and metabolic disorders” Thyroid diseases may contribute to autoimmune skin diseases, and more research is needed on their relationship.
12 citations,
May 2017 in “Pharmacology & therapeutics” Targeting immune tolerance issues in Alopecia Areata could restore hair growth and maintain remission.
11 citations,
December 2018 in “Journal of the European Academy of Dermatology and Venereology” Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
9 citations,
May 2008 in “Journal of Clinical Oncology” A woman's ovarian tumor causing high testosterone was successfully removed, and her symptoms improved.
9 citations,
May 2005 in “Expert Review of Clinical Immunology” Blocking interferon-gamma might help treat various autoimmune diseases.
9 citations,
July 2002 in “Journal of the European Academy of Dermatology and Venereology” The document concludes that fexofenadine reduces inflammation in chronic hives, cholestyramine helps half of pregnant women with itchy rashes, and relaxing incisions are a good alternative in facial surgery for the elderly.
7 citations,
June 2015 in “Cutaneous and Ocular Toxicology” Some drugs can cause skin reactions, which may improve when the drug is stopped, and rapid diagnosis and stopping the drug is crucial.
6 citations,
July 2015 in “Journal of Investigative Dermatology” Chicken feather gene mutation helps understand human hair disorders.
4 citations,
April 2010 in “Expert review of dermatology” Restoring immune privilege in hair follicles could help treat certain types of hair loss.
3 citations,
May 2023 in “Frontiers in immunology” Faulty inflammasome activation may lead to autoimmune skin diseases and could be a target for new treatments.
2 citations,
January 2019 The document concludes that autoimmune skin disorders are treated with corticosteroids and immunosuppressive drugs.
1 citations,
January 2020 in “Benha Journal of Applied Sciences” Certain gene variations may increase the risk and severity of alopecia areata.
Baricitinib may effectively treat oral lichen planus.
August 2023 in “Sabuncuoglu Serefeddin Health Sciences” CT60 polymorphism might increase the risk of Alopecia Areata.
COVID-19 may trigger or worsen rapid hair loss in alopecia areata.
March 2019 in “Nasza Dermatologia Online” A man had both alopecia areata and lichen planus, which is uncommon.
January 2018 in “SOJ microbiology & infectious diseases” Etanercept, a psoriasis treatment, caused hair loss in a patient.
October 2016 in “Veterinary record case reports” A cat had a rare skin disorder with hair loss and scaling, linked to a suspected tumor.
January 2000 in “Expert Opinion on Therapeutic Patents” The document highlights various patents for new compounds with potential treatments for multiple diseases, including cancer, hormonal disorders, and diabetes.
238 citations,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
222 citations,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
176 citations,
August 2015 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.
159 citations,
October 2015 in “Science Advances” Blocking JAK-STAT signaling can lead to hair growth.